Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension

Table 1 Patient characteristics at erenumab initiation

	P1	P2	P3	P4	P5	P6	P7	Mean (SD)
Age (years)	42	34	46	24	36	25	25	33.1 (8.2)
Duration of IIH (years)	2	2	1	1	4	2	5	2.4 (1.5)
Headache exacerbation at IIH diagnosis	+++	+++	+++	+++	+++	+++	+++
Duration of headaches from resolution of papilloedema to initiation of erenumab (months)	12	3	3	3	24	6	3	7.7 (7.9)
Preventative drug class failure ^a	4	3	3	4	5	4	3	3.7 (0.8)
Preventative drug class trial ^b	3	2	1	0	4	1	1	1.7 (1.4)
Migraine family history	yes	no	missing	no	no	yes	no
Migraine prior to IIH	yes	yes	yes	no	no	yes	no
MmsHD 12 months prior	12	20	16	16	14	8	14	14.3 (3.5) p = 0.778
MmsHD at erenumab initiation	13	17	15	20	14	11	12	14.6 (3.1)
MHD 12 months prior	30	30	30	30	28	30	20	28.3 (3.7) p = 0.593
MHD at erenumab initiation	30	30	27	30	30	30	25	28.9 (2.0)
Headache severity (NRS) at erenumab initiation	5.7	5.2	7.2	7.3	5.2	4.5	7.1	6.0 (1.2)
Monthly analgesic days at erenumab initiation	2	6	6	20	7	4	12	8.1 (6.1)
HIT-6 score at erenumab initiation	68	65	70	75	66	68	63	67.9 (3.9)
Frisén grade at erenumab initiation (both eyes)	0	0	0	0	0	0	0	0
OCT global average RNFL thickness at Erenumab initiation worst eye (μm) ^c	118	93	123	113	107	118	103	110.7 (10.4)
BMI at erenumab initiation	31	46.2	35.2	37.3	42.1	29.4	28.8	35.7 (6.6)
IIH characteristics at erenumab initiation	B, T	B, T	B, T	B, D, T	B, D, T	D, T	B, T
Acetazolamide at erenumab initiation	no	no	no	no	no	500 mg	no

Patient clinical characteristics at erenumab initiation. Monthly values refer to the 30-day pre-treatment period. *, p values indicate changes from the 30-day pre-treatment period prior to erenumab initiation
^aFailure defined as any of: inadequate efficacy with appropriate dosing and treatment duration; intolerable adverse effects; contraindications preventing use
^bTrial defined as any of: inadequate efficacy with appropriate dosing and treatment duration; intolerable adverse effects
^cHeidelberg Engineering SPECTRALIS, Heidelberg, Germany
+++ severe
Abbreviations: P Patient, IIH Idiopathic intracranial hypertension, MmsHD Monthly moderate/severe headache days, MHD Monthly headache days, NRS Numeric Rating Scale (0 = no pain to 10 = worst imaginable pain), HIT-6 Headache impact test-6, BMI Body mass index, B Blurred vision, D double vision, T Tinnitus, V Visual obscurations, OCT Optical coherence tomography, RNFL Retinal nerve fiber layer

ISSN: 1129-2377